Cellbox Solutions’ Post

BiolineRx (Nasdaq: BLRX). Market cap is $128M. I expect the company to earn about $100M in revenues after 2 years from APHEXDA sales and the Asian licensing agreement. A conservative sales to market capitalization ratio would be 3. That would set a market cap at $300M. Based on 60 million shares, the expected share price would be $5. These figures do not include any European agreements. To sell on today's news would be myopic.

Facebook Twitter LinkedIn Polynovo came out of a trading halt this morning to climb over 10% in afternoon trade, after reporting revenue increase of 119% during August. Polynovo Financial Update Polynovo reported that its August revenue, including funds received from the Biomedical Advanced Research and Development Authority (BARDA) was A$7.7 million, up 118.7% over the prior year.  YTD August total revenue was A$14.9M up by 92.7% over the prior year of A$7.7M. Sales from the U.S. look to be driving a lot of the growth, with the first two months of FY24 seeing growth of 85.3% to A$10.6 million. The […]

Why should IVD companies invest in contract manufacturing?     👉 Expertise  By working with an experienced contract manufacturer, IVD companies can benefit from specialized knowledge in areas like assay development, reagent manufacturing, and quality control.     👉 Compliance  There’s no denying the IVD industry is highly regulated. Reputable contract manufacturers have established quality management systems and adhere to the most stringent regulatory requirements.      👉 Flexibility   IVD companies tend to experience fluctuations in demand. Contract manufacturing provides the flexibility to scale production up or down, without the need to invest in additional resources.     CorDx provides world-class, end-to-end diagnostics development—from R&D to global distribution. Our integrated supply chain is just the beginning.     Learn more: bit.ly/3SIGHNn #ContractManufacturing #MedicalDevices #IVD 

Global #terminal #sterilization #services market size is expected to reach $20.23 Bn by 2028 at a rate of 11.9%, segmented as by type, contract sterilization services, sterilization validation services Major companies operating in the terminal sterilization services market report are Steris PLC, Getinge Group, TSO3 Inc., Olympus Corporation, Matachana Group Read More @https://lnkd.in/giyc_UfH #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

Stifel is projecting peak worldwide sales of $364 million by 2029 for Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s Eroxon, an innovative gel-based treatment for erectile dysfunction (ED). According to the US investment bank, most of these sales, $223 million, are expected from the US market, with Europe contributing an additional $117 million by 2028. This forecast underscores the significant market potential for Eroxon, which has already received marketing approval in the United States, the European Union, and the United Kingdom. Eroxon stands out in the ED market, which is valued at around $3.5 billion and growing at a compound annual growth rate of 13%, by offering a drug-free treatment option that acts within 10 minutes of application. This rapid onset of action and its availability without a prescription make Eroxon a unique product, especially appealing given its broader safety profile and... More at #Proactive #ProactiveInvestors http://ow.ly/e7Gh105pZ2q

Stenocare just published our Q4 report, and I had the pleasure to discuss the highlights with Helge Larsen from Proinvestor.com

EQRx, a Cambridge-based biopharmaceutical company that develops new treatments for rare diseases, has been in the spotlight recently. 🤔 The company had limited buyer interest, so they tried acquiring other companies before Revolution came in and bought them out for cash. 💰 It's not often that a company decides to go this route. But after seeing a potential in EQRx, Revolution made the call to invest in them - and it paid off! 🤩 This is a great example of the power of taking calculated risks and investing in the right companies. 💪 It just goes to show that with the right vision and strategy, anything is possible. 🤗 #EQRx #Revolution #Investing

ABL Bio announced KRW 49 billion in sales and KRW 12.8 billion in operating profit through its semi-annual report. This consecutive surplus is more meaningful because earnings are all from R&D based sales of license-out and it is a rare case for an R&D based business model that requires huge cost for R&D. With financial stability, ABL Bio has managed its business without any capital increase or debt borrowing since IPO. Company now has 7 clinical stage pipelines and 15 ongoing global clinical trials with various indications and countries including pipelines signed on license-out. In addition to clinical trials, ABL Bio has successfully done patent registrations and academic activities. As clinical trials of pipelines keep progressing, it is expected that there are many opportunities for ABL Bio to increase the value of the company and improve sustainability of management. #Earnings #Surplus #Research_and_Development #Sustainability

My team can assist with identifying risks in your temperature sensitive supply chain! Ask me how…#cryoportconsultingservices #proofinthedata

Follow the link below and find out what we can do to help support your clinical and commercial programs! From strategic guidance to hands-on assistance, our teams are primed and eager to collaborate with you, propelling your success to new heights! #EnableTheOutcome #SupplyChain #BioServices #LifeSciences #CellTherapy #GeneTherapy #ReproductiveMedicine #AnimalHealth #CryoportSystems